{
    "clinical_study": {
        "@rank": "109090", 
        "acronym": "TaISENWITCH", 
        "arm_group": {
            "arm_group_label": "Raltegravir switch", 
            "arm_group_type": "Other", 
            "description": "Isentress (400mg) bid + 2 NRTI (at least 2 nucleoside or nucleotide reverse transcriptase inhibitors and no other protease inhibitors)"
        }, 
        "brief_summary": {
            "textblock": "Switching from the ritonavir-boosted protease inhibitor component to raltegravir in stable\n      HIV-infected adult patients receiving combination therapy will demonstrate improved clinical\n      tolerability or lipid profiles with sustained plasma virological response (<50 copies/ml)."
        }, 
        "brief_title": "Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "HIV Infection", 
            "Adverse Drug Reaction", 
            "Quality of Life"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Drug Toxicity"
            ]
        }, 
        "detailed_description": {
            "textblock": "A. Objectives To compare the treatment-emerged AEs and virological suppression after switch\n      to raltegravir-based therapy in stable HIV-infected patients who receiving ritonavir-boosted\n      protease inhibitor antiretroviral regimen\n\n      Primary endpoints:\n\n        1. The changes in overall incidence and severity of patient-reported clinical adverse\n           events (based on \"symptom distress module) after switch to raltegravir-based therapy.\n\n        2. The changes in laboratory adverse event, e.g., the mean percent changes from baseline\n           to 48 weeks in plasma lipid profile (total cholesterol, LDLCholesterol, HDL\n           Cholesterol, triglycerides) after switch\n\n        3. The proportion of patients who are free of \"treatment failure\" at week 48 after switch\n\n      Secondary endpoints:\n\n        1. The proportion of patients who are free of \"virological failure\" at week 48 after\n           switch\n\n        2. The change from baseline in CD4 cell counts at week 48 after switch\n\n        3. The change in quality of life by assess the changes in the domain scores of   MOS-HIV\n           questionnaire at baseline and different study time points.\n\n      Safety endpoints\n\n        1. Incidence of adverse events\n\n        2. The proportion of patients with treatment-related grade 3 or 4 adverse events and\n           laboratory abnormalities"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who are infected with HIV-1\n\n          -  Ages at least 20 years\n\n          -  Patients are currently receiving a ritonavir-boosted PI-based regimen, including\n             lopinavir, atazanavir, or darunavir, plus at least 2 antiretroviral agents (NRTIs)\n\n          -  Patient complained of treatment-emerged clinical adverse events or abnormal lipid\n             profile\n\n          -  Patients with plasma HIV-1 viral RNA below 50 copies per ml for at least 6 months\n\n        Exclusion Criteria:\n\n          -  Patient with known history of contraindication or hypersensitivity to any component\n             of the study regimen\n\n          -  Patients with acute or decompensated chronic hepatitis in the previous 6 months\n\n          -  Patients with chronic hepatitis and serum aminotransferase concentrations are more\n             than 5 times the upper limit of the normal range\n\n          -  Patients with renal insufficiency (patients need dialysis or have serum creatinine\n             concentrations of more than twice the upper limit of the normal range\n\n          -  Current alcohol or substance abuse (patients receiving methadone for the management\n             of withdrawal symptoms due to substance abuse are allowed )\n\n          -  Patients have failed previous regimens (prior to starting the current 2NRTI+PI/r\n             regimen they are currently on)\n\n          -  Patient's viral load have not been consistently <50 copies per ml for 6 months or\n             longer.\n\n          -  Patients initiated lipid lowering agents during the preceding 3 months\n\n          -  Patients with any medical disorder or history of any illness which, in the opinion of\n             the investigator, that the use of study medications is contraindicated or might\n             confound the results of the study or pose additional risk in administering study\n             drugs to the patient\n\n          -  Pregnant, wish to become pregnant during the study period or breastfeeding women\n\n          -  Patients who are lack of expectation to maintain assigned study medication during\n             study period\n\n          -  Patients who have received therapy with investigational drugs in the previous 3\n             months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01679964", 
            "org_study_id": "MISP40301", 
            "secondary_id": "MISP 40301"
        }, 
        "intervention": {
            "arm_group_label": "Raltegravir switch", 
            "description": "Isentress (400mg) bid + 2 NRTI (at least 2 nucleoside or nucleotide reverse transcriptase inhibitors and no other protease inhibitors)", 
            "intervention_name": "Raltegravir switch", 
            "intervention_type": "Drug", 
            "other_name": "Isentress"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Protease Inhibitors", 
                "HIV Protease Inhibitors", 
                "Reverse Transcriptase Inhibitors"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "HIV infection", 
            "Raltegravir", 
            "Adverse event", 
            "Life quality"
        ], 
        "lastchanged_date": "September 5, 2012", 
        "location": [
            {
                "contact": {
                    "email": "kmtthidchen@gmail.com", 
                    "last_name": "Tun-Chieh Chen, M.D.", 
                    "phone": "+886-7-2911101", 
                    "phone_ext": "8960"
                }, 
                "facility": {
                    "address": {
                        "city": "Kaohsiung", 
                        "country": "Taiwan", 
                        "zip": "807"
                    }, 
                    "name": "Kaohsiung Medical University Chung-Ho Memorial Hospital"
                }, 
                "investigator": {
                    "last_name": "Tun-Chieh Chen, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "ed100233@yahoo.com.tw", 
                    "last_name": "Hsi-Hsun Lin, MD", 
                    "phone": "+886-7-615-0011", 
                    "phone_ext": "5550"
                }, 
                "facility": {
                    "address": {
                        "city": "Kaohsiung", 
                        "country": "Taiwan", 
                        "zip": "824"
                    }, 
                    "name": "E-Da Hospital"
                }, 
                "investigator": {
                    "last_name": "Hsi-Hsun Lin, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cmchid@yahoo.com.tw", 
                    "last_name": "Mao-Wang Ho, M.D.", 
                    "phone": "+886-4-22076681"
                }, 
                "facility": {
                    "address": {
                        "city": "Taichung", 
                        "country": "Taiwan", 
                        "zip": "40447"
                    }, 
                    "name": "China Medical University Hospital"
                }, 
                "investigator": {
                    "last_name": "Mao-Wang Ho, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "winston3415@gmail.com", 
                    "last_name": "Wen-Chien Ko, M.D.", 
                    "phone": "+886-6-2353535", 
                    "phone_ext": "3596"
                }, 
                "facility": {
                    "address": {
                        "city": "Tainan", 
                        "country": "Taiwan", 
                        "zip": "704"
                    }, 
                    "name": "National Cheng Kung University Hospital"
                }, 
                "investigator": {
                    "last_name": "Wen-Chien Ko, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "hsmaids@hotmail.com", 
                    "last_name": "Szu-Min Hsieh, M.D.", 
                    "phone": "+886-2-23123456", 
                    "phone_ext": "66842"
                }, 
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan", 
                        "zip": "10048"
                    }, 
                    "name": "National Taiwan University Hospital"
                }, 
                "investigator": {
                    "last_name": "Szu-Min Hsieh, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "DAD85@tpech.gov.tw", 
                    "last_name": "Bor-Shen Hu, M.D.", 
                    "phone": "+886-2-23889595", 
                    "phone_ext": "2801"
                }, 
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan", 
                        "zip": "108"
                    }, 
                    "name": "Taipei City Hospital"
                }, 
                "investigator": {
                    "last_name": "Bor-Shen Hu, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "chingtaihuang@gmail.com", 
                    "last_name": "Ching-Tai Huang, M.D.", 
                    "phone": "+886-3-3281200", 
                    "phone_ext": "8450"
                }, 
                "facility": {
                    "address": {
                        "city": "Taoyuan", 
                        "country": "Taiwan", 
                        "zip": "333"
                    }, 
                    "name": "Chang Gung Memorial Hospital at Linkou"
                }, 
                "investigator": {
                    "last_name": "Ching-Tai Huang, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single Arm Study to Assess the Sustained Virological Suppression and Improvement of Treatment-emerged Adverse Events of Switching to Raltegravir in Stable HIV-infected Patients on Ritonavir-boosted Protease Inhibitor Regimen", 
        "overall_contact": {
            "email": "ed100233@yahoo.com.tw", 
            "last_name": "Hsi-Hsun Lin, MD", 
            "phone": "+886-76150011", 
            "phone_ext": "5550"
        }, 
        "overall_official": {
            "affiliation": "E-DA Hospital", 
            "last_name": "Hsi-Hsun Lin, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Taiwan: Department of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The proportion of patient-reported clinical adverse events in total and by severity (based on symptom distress module) at 4 weeks, The proportion of patient-reported clinical adverse events in total and by severity (based on symptom distress module) at 12-16 weeks, The proportion of patient-reported clinical adverse events in total and by severity (based on symptom distress module) at 28-32 weeks, The proportion of patient-reported clinical adverse events in total and by severity (based on symptom distress module) at 48 weeks", 
                "measure": "The proportion of patient-reported clinical adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Week 4, 12-16, 28-32, 48"
            }, 
            {
                "description": "The percent changes from baseline in plasma lipid profiles (total cholesterol, LDL Cholesterol, HDL Cholesterol, triglycerides) at 4 weeks, The percent changes from baseline in plasma lipid profiles (total cholesterol, LDL Cholesterol, HDL Cholesterol, triglycerides) at 12-16 weeks, The percent changes from baseline in plasma lipid profiles (total cholesterol, LDL Cholesterol, HDL Cholesterol, triglycerides) at 28-32 weeks, The percent changes from baseline in plasma lipid profiles (total cholesterol, LDL Cholesterol, HDL Cholesterol, triglycerides) at 48 weeks", 
                "measure": "The percent changes from baseline in plasma lipid profiles (total cholesterol, LDL Cholesterol, HDL Cholesterol, triglycerides)", 
                "safety_issue": "Yes", 
                "time_frame": "Week 4, 12-16, 28-32, 48"
            }, 
            {
                "description": "The proportion of patients with treatment failure at 4 weeks, The proportion of patients with treatment failure at 12-16 weeks, The proportion of patients with treatment failure at 28-32 weeks, The proportion of patients with treatment failure at 48 weeks", 
                "measure": "The proportion of patients with treatment failure", 
                "safety_issue": "No", 
                "time_frame": "Week 4, 12-16, 28-32, 48"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01679964"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The proportion of patients who are free of \"virological failure\" at week 4 after switch, The proportion of patients who are free of \"virological failure\" at week 12-16 after switch, The proportion of patients who are free of \"virological failure\" at week 28-32 after switch, The proportion of patients who are free of \"virological failure\" at week 48 after switch", 
                "measure": "The proportion of patients who are free of \"virological failure\"", 
                "safety_issue": "No", 
                "time_frame": "Week 4, 12-16, 28-32, 48"
            }, 
            {
                "description": "The change from baseline in CD4 cell counts at week 4 after switch, The change from baseline in CD4 cell counts at week 12-16 after switch, The change from baseline in CD4 cell counts at week 28-32 after switch, The change from baseline in CD4 cell counts at week 48 after switch", 
                "measure": "The change from baseline in CD4 cell counts", 
                "safety_issue": "No", 
                "time_frame": "Week 4, 12-16, 28-32, 48"
            }, 
            {
                "description": "The change from baseline in quality of life (based on the MOS-HIV questionnaire) at week 12-16 after switch, The change from baseline in quality of life (based on the MOS-HIV questionnaire) at week 48 after switch.", 
                "measure": "the change from baseline in life quality (based on the MOS-HIV questionnaire)", 
                "safety_issue": "No", 
                "time_frame": "week 12-16, 48"
            }
        ], 
        "source": "Lin, Hsi-Hsun, M.D.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lin, Hsi-Hsun, M.D.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}